Zelluna selected Medpace to manage its Phase I study of ZI‑MA4‑1, an allogeneic TCR‑NK cell therapy targeting MAGE‑A4 in advanced solid tumors. The CRO contract covers study operations, regulatory support, data analysis and pharmacovigilance as the company transitions into the clinic. Zelluna is advancing an off‑the‑shelf platform combining tumor‑targeting T cell receptors with natural killer cell backbones. The trial is slated to enroll patients with lung, ovarian, head and neck cancers and sarcomas, and initial clinical data are expected by mid‑2026, per company statements. Zelluna also noted prior regulatory interactions, a manufactured GMP batch ready for trial use, and planned UK trial sites including Christie NHS Foundation Trust and the Royal Marsden.